Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes

Bipolar Depression Clinical Trial

Official title:

Study of FK949E - An Open-label, Two-way Crossover Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02362412
• Other study ID #: 6949-CL-0023
• Status: Completed
• Phase: Phase 3
• Start date: February 18, 2015
• Est. completion date: February 6, 2016

Study information

• Verified date: January 2019
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of switching FK949E (sustained-release quetiapine) 50-mg and 150-mg tablets to the other tablet at the equivalent total daily dose in bipolar disorder patients with major depressive episodes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: February 6, 2016
• Est. primary completion date: February 6, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 64 Years

Eligibility

Inclusion Criteria:

• Diagnosis of bipolar I or II disorder as specified in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR), with a major depressive episode.

• Able to participate in the study with understanding of and compliance with subject requirements during the study in the investigator's or subinvestigator's opinion.

Exclusion Criteria:

• Concurrent or previous history of DSM-IV-TR Axis I disorders, except bipolar disorder, within the last 6 months before informed consent.

• Concurrence of DSM-IV-TR Axis II disorder that is considered to greatly affect patient's current mental status.

• The Young Mania Rating Scale (YMRS) total score of 13 points or more.

• Nine or more mood episodes within the last 12 months before informed consent.

• Lack of response to at least 6-week treatment with at least 2 antidepressants for the current major depressive episode in the investigator's or subinvestigator's opinion.

• The current major depressive episode persisting for less than 4 weeks before informed consent.

• History of substance dependence (other than caffeine and nicotine) or alcohol abuse or dependence.

• Treatment with a depot antipsychotic within the last 49 days before the start of the pre-treatment observation period.

• Unable to suspend antipsychotics or antidepressants after the start of the pre-treatment observation period.

• Treatment with more than one of the following three drugs, mood stabilizers (lithium carbonate and/or sodium valproate) and lamotrigine, if these drugs, except one of either drugs, cannot be suspended after the start of the pre-treatment observation period.

• Unable to suspend antiepileptics (except lamotrigine and sodium valproate), antianxiety agents, hypnotics, sedatives, psychostimulants, antiparkinsonian agents, cerebral ameliorators, antidementia agents, or anorectics, except those specified as conditionally-allowed concomitant drugs, from 7 days before the start of the pre-treatment observation period.

• Unable to suspend CYP3A4 inhibitors or inducers, or monoamine oxidase (MAO) inhibitors from 7 days before the start of the pre-treatment observation period.

• Electroconvulsive therapy within the last 83 days before the start of the pre-treatment observation period.

• A possible need of psychotherapy during the study period (unless the therapy has been commenced at least 83 days before the start of the pre-treatment observation period).

• The Hamilton Depression Rating Scale (HAM-D17) suicide score of 3 points or more, history of suicide attempt within the last 6 months before informed consent, or the risk of suicide in the investigator's or subinvestigator's opinion.

Related Conditions & MeSH terms

• Bipolar Depression
• Bipolar Disorder
• Depression
• Depressive Disorder
• Depressive Disorder, Major

Intervention

Drug:
• FK949E
A tablet containing 50 mg or 150 mg of quetiapine taken orally.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Inc

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Montgomery-Asberg Depression Rating Scale (MADRS) Total Score	The MADRS is a 10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.	Week 8 of each treatment period (Week 12 and Week 20)
Secondary	Hamilton Depression Scale (HAM-D17)	The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52 with lower scores indicating less depressive symptoms.	Week 8 of each treatment period (Week 12 and Week 20)
Secondary	Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S): Overall Bipolar Illness	The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (Normal, not ill) to 7 (very severely ill).	Week 8 of each treatment period (Week 12 and Week 20)
Secondary	Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S):Depression	The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (Normal, not ill) to 7 (very severely ill).	Week 8 of each treatment period (Week 12 and Week 20)
Secondary	Clinical Global Impression-Bipolar-Severity of Illness (CGI-BP-S): Mania	The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (Normal, not ill) to 7 (very severely ill)	Week 8 of each treatment period (Week 12 and Week 20)
Secondary	Clinical Global Impression-Bipolar-Change (CGI-BP-C):Overall Bipolar Illness	The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.	Week 8 of each treatment period (Week 12 and Week 20)
Secondary	Clinical Global Impression-Bipolar-Change (CGI-BP-C):Depression	The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.	Week 8 of each treatment period (Week 12 and Week 20)
Secondary	Clinical Global Impression-Bipolar-Change (CGI-BP-C):Mania	The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.	Week 8 of each treatment period (Week 12 and Week 20)
Secondary	Number of Participants With Adverse Events	An adverse event (AE) is defined as any undesirable or unintended sign (including abnonmal laboratory test values), symptom, or disease occurring while the study drug was administered, regardless of whether or not there was a causal relationship with the study drug. A serious AE is defined as a an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important.	Up to 22 weeks

External Links

•   Link to results on Astellas Clinical Study Results website